Page 2 - Tim Goodnow News Today

Operator: Good day, and welcome to the Senseonics First Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.

Senseonics Holdings, Inc. , a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, today... | May 9, 2023

Cautionary Note Regarding Forward-Looking Statements Any statements in this presentation about future expectations, plans and... | March 15, 2023

Senseonics to report fourth quarter and full year 2022 financial results after market close March 15, 2023 with results to be discussed during the event ... | February 17, 2023

Senseonics (NYSE:SENS) and Ascensia Diabetes Care today launched a collaboration with the Nurse Practitioner Group (NPG).

First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense® E3 CGMGERMANTO...

The long-term implantable E3 CGM system now approved for commercialization in select European markets Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development

Senseonics' FDA-approved CGM has a sensor that lasts six months, a first for any CGM. Other competing solutions from Medtronic and Dexcom last anywhere between three to 10 days.

The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months for adults with diabetes, according to a company press release. Senseonics’s Eversense E3 continuous glucose monitoring system is a fully implantable third-generation sensor that connects to a removable smart transmitter and mobile app displaying glucose values, trends and

- Real-time glucose data and alerts from the world's first and only long-term CGM system can now be remotely monitored by friends and family of Eversense users on Android and iOS operating system Senseonics